CJC-1295 (no DAC) vs Tesamorelin
Truncated GHRH(1-29) against full-length GHRH(1-44). Sequence length is the whole distinction and it is routinely glossed over.
Growth Hormone
CJC-1295 (no DAC)
Modified GRF (1-29) analog with four amino acid substitutions conferring resistance to enzymatic degradation.
Growth Hormone
Tesamorelin
Stabilized 44-amino-acid GHRH analog — the longest GHRH sequence in common research use.
Side by side
| Dimension | CJC-1295 (no DAC) | Tesamorelin |
|---|---|---|
| Molecular weight | 3367.9 g/mol | 5135.86 g/mol |
| Size class | mid-length peptide | long peptide |
| CAS number | 863288-34-0 | 218949-48-5 |
| Research area | growth hormone | growth hormone |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 5mg, 10mg | 10mg, 15mg |
| Entry price | $39 | $64 |
| Cost per mg | $5.80 | $5.93 |
Mechanism
CJC-1295 (no DAC)
CJC-1295 without DAC — more precisely Modified GRF (1-29) — is a 29-amino-acid GHRH analog carrying four substitutions (D-Ala2, Gln8, Ala15, Leu27) that increase stability against DPP-4 cleavage and plasma degradation. The 'no DAC' designation distinguishes it from the drug affinity complex variant, which incorporates a maleimido group for albumin conjugation and a substantially longer half-life. The two are frequently conflated in supplier catalogs; they are pharmacokinetically very different molecules.
Tesamorelin
Tesamorelin is a synthetic analog of full-length human GHRH(1-44) with a trans-3-hexenoyl group attached at the N-terminus, conferring resistance to DPP-4 cleavage. It is distinguished from sermorelin and Modified GRF (1-29) by sequence length: those are truncated to the first 29 residues, whereas tesamorelin retains the complete 44-residue sequence. It has an established clinical literature, which is uncommon in this catalog.
Research applications
CJC-1295 (no DAC)
- GHRH receptor binding and activation studies
- Comparative half-life studies against DAC-conjugated variants
- Combination studies with GHS-R1a agonists
- Enzymatic stability and degradation kinetics
Tesamorelin
- GHRH receptor binding and activation studies
- Comparative studies against truncated GHRH analogs
- Visceral adipose tissue metabolism research
- IGF-1 axis response profiling
Common questions
What is the difference between CJC-1295 (no DAC) and Tesamorelin?
CJC-1295 (no DAC) is modified GRF (1-29) analog with four amino acid substitutions conferring resistance to enzymatic degradation. Tesamorelin is stabilized 44-amino-acid GHRH analog — the longest GHRH sequence in common research use. They differ in molecular weight (3367.9 vs 5135.86 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, CJC-1295 (no DAC) or Tesamorelin?
CJC-1295 (no DAC) is lower at approximately $5.80 per milligram at its best tier, against $5.93 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can CJC-1295 (no DAC) and Tesamorelin be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should CJC-1295 (no DAC) and Tesamorelin be stored?
Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days. For Tesamorelin: Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
All products are intended strictly for laboratory research use. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not a drug, food, or cosmetic.
Comparison generated from NuVida Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.